Top entities: KC Pharmaceuticals, United States — Food and Drug Administration, Cardinal Health.

What category does this event fall under?

Regulatory — classified as product recall.

What is the sentiment of coverage?

Aggregate sentiment score: -10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

United States — Food and Drug Administration classified recall · KC Pharmaceuticals recalled · United States — Food and Drug Administration designated recall KC Pharmaceuticals

Is this event still developing?

This is an active story, last updated Jul 29, 2026. Coverage continues to evolve.

Regulatory product recall

Levothyroxine recall by Major Pharmaceuticals

Q: When did this event occur?

First reported Jul 24, 2026; last updated Jul 29, 2026.

Q: What is the market impact?

General. The recall may affect patient trust and lead to temporary supply disruptions.

Analysis based on 12 articles · First reported Jul 24, 2026 · Last updated Jul 29, 2026

Sentiment

-10

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recall may affect patient trust and lead to temporary supply disruptions. However, the impact is limited as the recall is Class II and alternatives are available.

pharmaceutical

Event Summary

KC Pharmaceuticals initiated a nationwide recall of levothyroxine sodium tablets on July 13, 2026, due to subpotency. The FDA classified it as a Class II recall on July 17. The recall covers multiple strengths in 100-tablet cartons and 10-tablet blister packs distributed by KC Pharmaceuticals and Cardinal Health. Patients are advised not to stop medication without consulting a healthcare provider.

Key Actions

80 United States — Food and Drug Administration classified recall

75 KC Pharmaceuticals recalled

50 United States — Food and Drug Administration designated recall KC Pharmaceuticals

Entities Involved

priv

KC Pharmaceuticals

Initiator of the recall; faces potential reputational damage and financial liability.

Importance 100.0 Sentiment -30.0

govactor

United States — Food and Drug Administration

Regulatory body that classified the recall; performing its oversight role.

Importance 60.0 Sentiment 0.0

stock

Cardinal Health

Co-distributor of affected products; may face minor reputational impact.

Importance 50.0 Sentiment -20.0

Relationships

KC Pharmaceuticals related ↔ United States — Food and Drug Administration

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard